ArticleDiscover oncology2026
Bibliometric analysis and knowledge mapping of thoracic SMARCA4-deficient undifferentiated tumor.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a rare and highly aggressive malignancy with poor prognosis and no established standard therapy. This study aimed to map the research landscape of SMARCA4-UT through bibliometric analysis to guide clinical decision-making and research prioritization.
methodsPublications on thoracic SMARCA4-UT were retrieved from the Web of Science Core Collection and Scopus from 2000 to 2025. After screening, 132 articles and reviews were included. Bibliometrix and CiteSpace were used to analyze publication trends, geographic and institutional distribution, author productivity, collaboration networks, keyword evolution, thematic structure, and highly cited articles.
resultsSMARCA4-UT research expanded rapidly, with 31.95% annual growth rate and 32.25 average citations per article, reflecting rising academic impact. China (28.8%) and Japan (23.5%) led global output, forming a China-US dual-core collaboration network. Mechanistic studies on the SWI/SNF complex and BRG1 are mature, while clinical and therapeutic research remains underdeveloped. Temporal analysis revealed a shift toward diagnostic standardization after the 2021 WHO classification.
conclusionsSMARCA4-UT research is in a rapid growth phase, with a substantial gap between mechanistic advances and clinical translation. Immunochemotherapy is the current first-line backbone, while targeted and combinatorial strategies remain exploratory. These findings provide evidence-based guidance for clinical practice and research design, highlighting the urgent need for biomarker-driven therapy and large-scale international collaboration to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.